Adapting Cancer Immunotherapy Models for the Real World.
Adapting Cancer Immunotherapy Models for the Real World.
复制标题
DOI：
10.1016/j.it.2016.03.010
复制
发表时间：
2016-06
影响因子：
16.8
通讯作者：
Teague RM
中科院分区：
文献类型：
--
作者：
Klevorn LE;Teague RM
在小鼠身上的早期实验预测了检查点阻断免疫疗法在癌症患者中的成功。然而，这些相同的动物研究未能准确预测治疗的许多局限性和毒性。造成这种差异的可能原因之一是几乎普遍使用健康的幼鼠，它们与不同的患者群体在年龄、体重、饮食和卫生方面形成了鲜明的对比。由于这些变量影响免疫和新陈代谢，它们也影响免疫治疗的结果，应纳入临床前实验的研究设计。在这里，我们讨论最近的发现，这些发现强调了癌症免疫治疗的有效性和毒性如何受到患者变异的影响，以及如何在动物研究中更好地模拟不同的宿主环境。
Early experiments in mice predicted the success of checkpoint blockade immunotherapy in cancer patients. However, these same animal studies failed to accurately predict many of the limitations and toxicities of treatment. One of the likely reasons for this discrepancy is the nearly universal use of young healthy mice, which stand in stark contrast to diverse patient populations varying in age, weight, diet and hygiene. Because these variables impact immunity and metabolism, they also influence outcomes during immunotherapy and should be incorporated into the study design of preclinical experiments. Here, we discuss recent findings that highlight how efficacy and toxicity of cancer immunotherapy are affected by patient variation, and how distinct host environments can be better modeled in animal studies.